Stevanato Group Reports Record Revenue of EUR1,104 Million for Fiscal Year 2024
- Introduces 2025 Guidance -
PIOMBINO DESE, Italy--(BUSINESS WIRE)--March 06, 2025--
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the fourth quarter and fiscal year 2024.
Fourth Quarter and Full-Year 2024 Highlights (comparisons to prior-year period)
-- Revenue for the fourth quarter of 2024 increased 3% to EUR330.6 million,
and high-value solutions represented 40% of total revenue, in line with
Company expectations.
-- For the fourth quarter, diluted earnings per share were EUR0.18, and
adjusted diluted earnings per share were EUR0.19.
-- Adjusted EBITDA margin increased 50 basis points to 27.5% for the fourth
quarter.
-- For fiscal year 2024, revenue increased 2% to EUR1,104 million, and
high-value solutions represented 38% of total revenue.
-- For fiscal year 2024, diluted earnings per share were EUR0.43, and
adjusted diluted earnings per share were EUR0.48.
-- Adjusted EBITDA margin for fiscal year 2024 was 23.5%.
-- The Company is establishing fiscal year 2025 guidance and expects revenue
in the range of EUR1,160 million to EUR1,190 million, adjusted EBITDA in
the range of EUR293.0 million to EUR306.3 million, and adjusted diluted
EPS between EUR0.51 and EUR0.55.
Fourth Quarter 2024 Results
For the fourth quarter of 2024, revenue increased 3% (3% on a constant currency basis) compared with the same period last year, to EUR330.6 million, driven by a 7% increase in the Company's Biopharmaceutical and Diagnostic Solutions (BDS) Segment, which offset the expected 16% decline in its Engineering Segment.
Revenue from high-value solutions increased to a record EUR131 million and represented 40% of total revenue for the fourth quarter of 2024, compared with 37% for the same period last year, driven primarily by increased customer demand for high-performance syringes. As expected, lower revenue from EZ-fill$(R)$ vials unfavorably impacted the mix within high-value solutions for the fourth quarter of 2024.
Gross profit margin for the fourth quarter of 2024 decreased by 210 basis points to 29.7%, compared with the same period last year, primarily due to the effects of vial destocking, and lower gross profit from the Engineering Segment. This was partially offset by a strong quarter in high-value solutions and year-over-year improvements in the Company's Fishers and Latina manufacturing facilities.
For the fourth quarter of 2024, operating profit margin increased 20 basis points to 20.2%, due to cost management initiatives. Adjusted operating profit margin increased 70 basis points to 21.5%
Full Year 2024 Results
Revenue for the full year increased 2% (2% on a constant currency basis) to EUR1,104 million, compared with the same period last year, driven by 6% growth in the BDS Segment, which was offset by a 17% decline from the Engineering Segment. Revenue from high-value solutions increased 15% to EUR422.3 million for fiscal year 2024, and represented 38% of total Company revenue compared with 34% last year.
As expected, gross profit margin for fiscal 2024 decreased to 27.4%, compared with 31.3% in 2023, mainly due to (i) lower bulk and EZ-fill(R) vial volumes related to vial destocking, (ii) lower gross profit from the Engineering Segment, and (iii) short-term inefficiencies tied to the start-up of the Company's new manufacturing facilities. As a result, operating profit margin was 14.6% and adjusted operating profit was 16.2% for fiscal 2024.
Franco Stevanato, Chairman and Chief Executive Officer, stated, "We finished the year with positive fourth quarter results, which were in line with our expectations. The increase in high-value solutions was driven by strong customer demand for high-performance syringes. We believe our growth investments are aligned to satisfy market needs to capitalize on the growing patient demand for biologics such as GLP1s and monoclonal antibodies. In 2024, revenue from biologics increased to 34% of BDS Segment revenue, compared with 30% in the same period last year. We continue to make meaningful progress on our Engineering optimization plan and are on track to complete the majority of the previously delayed projects by mid-year 2025."
Biopharmaceutical and Diagnostic Solutions Segment (BDS)
Revenue grew 7% (8% on a constant currency basis) to EUR279.4 million for the fourth quarter, and increased 6% (7% on a constant currency basis) to EUR933.7 million for fiscal 2024, compared with the same periods last year, driven primarily by growth in high-value syringes, which was partially offset by the expected revenue declines from bulk and EZ-fill(R) vials. The declines were more pronounced in EZ-fill(R) vials.
Revenue from high-value solutions increased to 47% and 45% of Segment revenue in the fourth quarter and full year, respectively.
For the fourth quarter of 2024, gross profit margin decreased to 31.1%, mostly due to the expected temporary effects from vial destocking, which was partially offset by a strong quarter in high-value solutions and improvements in Fishers and Latina as the Company continues to scale its manufacturing operations. For fiscal year 2024, gross profit margin decreased to 28.7% driven by: (i) vial destocking, and (ii) short term inefficiencies tied to the start-up phase of the Company's new manufacturing facilities.
Engineering Segment
Revenue from the Engineering Segment decreased 16% to EUR51.2 million for the fourth quarter, and 17% to EUR170.3 million for fiscal year 2024, compared with the same periods last year.
The Company remains focused on executing its business optimization plan and expects to complete all the previously delayed projects in 2025. The plan is designed to address current challenges, improve the overall health of the business and return the business to profitable growth.
As expected, gross profit margin decreased to 18.6% and 15.7% for the fourth quarter and full year of 2024, respectively.
Balance Sheet and Cash Flow
At December 31, 2024, the Company had cash and cash equivalents of EUR98.3 million and net debt of EUR335.0 million. The Company believes that it has available liquidity to fund its strategic priorities over the next twelve months through a combination of cash on hand, available credit, cash generated from operations, and the ability to access additional financing.
Capital expenditures totaled EUR80.0 million and EUR286.6 million for the fourth quarter and fiscal year 2024, respectively, as the Company continues to ramp-up capacity in response to customer demand for high-value solutions in Fishers, Indiana and Latina, Italy.
For fiscal 2024, cash flow from operating activities was EUR155.8 million. For the full year 2024, cash flow used for the purchase of property, plant, and equipment, and intangible assets totaled EUR313.6 million, driven primarily by capital expenditures supporting strategic initiatives. The combination of increased cash flow from operations and lower capex helped drive a significant year-over-year improvement in free cash flow. As result, negative free cash flow improved to EUR148.5 million for fiscal 2024, compared with negative free cash flow of EUR333.9 million for fiscal 2023.
2025 Guidance
The Company is introducing full year 2025 guidance and expects:
-- Revenue in the range of EUR1,160 million to EUR1,190 million; -- Adjusted EBITDA in the range of EUR293.0 million to EUR306.3 million; and -- Adjusted diluted EPS in the range of EUR0.51 to EUR0.55.
Franco Stevanato concluded, "Looking to 2025, we remain focused on executing our key priorities and achieving our long-term objectives. The fundamentals of our business are strong, as we operate in growing end markets with favorable secular tailwinds. We continue to deliver organic growth driven by solid demand for high value solutions, and we expect to increasingly benefit from our ongoing capacity expansion projects as they continue to scale and mature. We enjoy an enviable market position and our unique value proposition makes us a partner of choice for customers. Above all, we are committed to putting the business on the right path to return to double-digit growth, expand margins and build long-term shareholder value."
Conference call: The Company will host a conference call and webcast at 8:30 a.m. $(ET)$ on Thursday, March 6, 2025, to discuss financial results. During the call, management will refer to a slide presentation which will be available on the morning of the call on the "Financial Results" page under the Investor Relations section of the Company's website.
Pre-registration: Participants who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. We encourage participants to pre-register for the conference call using the following link: STVN conference call pre-registration.
Webcast: A live, listen-only webcast of the call will be available at the following link: STVN webcast.
Dial in: Those who are unable to pre-register may dial in by calling:
Italy: +39 02 802 09 11 United Kingdom: +44 1 212 818004 United States: +1 718 705 8796 United States Toll Free: +1 855 265 6958
Questions during the call: Participants who wish to ask questions during the call should use the HD webphone link: https://hditalia.choruscall.com/?$Y2FsbHR5cGU9MiZpbmZvPWNvbXBhbnk=.
Replay: The webcast will be archived for three months on the Company's Investor Relations section of its website.
Forward-Looking Statements
This press release may include forward-looking statements. The words "establishing," "expects," "believe," "growing," "continue," "remains," "improve," "return," "growth," "increasingly," "believes," "continues," "remaining," "are strong," "solid," "ongoing," "enjoy," "are committed," "expand," "build," and similar expressions (or their negative) identify certain of these forward-looking statements. These forward-looking statements are statements regarding the Company's intentions, beliefs or current expectations concerning, among other things, the Company's future financial performance, including revenue, operating expenses and ability to maintain profitability and operational and commercial capabilities; the Company's expectations regarding the development of the industry and the competitive environment in which it operates; the expansion of the Company's plants and its expectations to increase production capacity; the global supply chain and the Company's committed orders; customer demand and customers' ability to destock higher inventories accumulated during the COVID-19 pandemic; the success of the Company's initiatives to optimize the industrial footprint, harmonize processes and enhance supply chain and logistics strategies; the Company's geographical and industrial footprint; and the Company's goals, strategies and investment plans. The forward-looking statements in this press release are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which the Company will operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward looking statements. Many of these risks and uncertainties relate to factors that are beyond the Company's ability to control or estimate precisely, such as conditions in the U.S. capital markets, negative global economic conditions, inflation, the impact of the conflict between Russia and the Ukraine, the evolving events in Israel and Gaza, supply chain and logistical challenges and other factors such as the Company's ability to continue to obtain financing to meet its liquidity needs, changes in the geopolitical, social and regulatory framework in which the Company operates or in economic or technological trends or conditions. For a description of the risks that could cause the Company's future results to differ from those expressed in any such forward looking statements, refer to the risk factors discussed in our most recent annual report on Form 20-F filed and our most recent filings with the U.S. Securities and Exchange Commission. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. Except as required by law, the company assumes no obligation to update any such forward-looking statements.
Non-GAAP Financial Information
This press release contains non-GAAP financial measures. Please refer to the tables included in this press release for a reconciliation of non-GAAP financial measures.
Management monitors and evaluates our operating and financial performance using several non-GAAP financial measures, including Constant Currency Revenue, EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Operating Profit, Adjusted Operating Profit Margin, Adjusted Income Taxes, Adjusted Net Profit, Adjusted Diluted EPS, Capital Employed, Net Cash/Net Debt, Free Cash Flow, and CAPEX. The Company believes that these non-GAAP financial measures provide useful and relevant information regarding its performance and improve its ability to assess our financial condition. While similar measures are widely used in the industry in which the Company operates, the financial measures it uses may not be comparable to other similarly titled measures used by other companies, nor are they intended to be substitutes for measures of financial performance or financial position as prepared in accordance with IFRS.
About Stevanato Group
Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group's core capabilities in scientific research and development, its commitment to technical innovation, and its engineering excellence are central to its ability to offer value added solutions to clients. To learn more, visit: www.stevanatogroup.com.
Consolidated Income Statement
(Amounts in EUR millions, except per share data)
For the three months For the years
ended December 31, ended December 31,
2024 % 2023 % 2024 % 2023 %
Revenue 330.6 100.0% 320.6 100.0% 1,104.0 100.0% 1,085.4 100.0%
Costs of Sales 232.4 70.3% 218.8 68.2% 801.7 72.6% 745.5 68.7%
----- ----- ----- ----- ------- ----- ------- -----
Gross Profit 98.2 29.7% 101.8 31.8% 302.3 27.4% 339.9 31.3%
Other Operating
Income 5.5 1.7% 3.0 0.9% 9.1 0.8% 10.4 1.0%
Selling and
Marketing
Expenses 5.9 1.8% 7.1 2.2% 24.9 2.3% 25.0 2.3%
Research and
Development
Expenses 5.6 1.7% 10.1 3.1% 31.7 2.9% 35.7 3.3%
General and
Administrative
Expenses 25.4 7.7% 23.6 7.4% 93.7 8.5% 88.9 8.2%
----- ----- ----- ----- ------- ----- ------- -----
Operating Profit 66.8 20.2% 64.0 20.0% 161.1 14.6% 200.7 18.5%
Finance Income 8.7 2.6% 4.3 1.4% 22.3 2.0% 20.3 1.9%
Finance Expense 10.9 3.3% 9.5 3.0% 23.2 2.1% 31.4 2.9%
----- ----- ----- ----- ------- ----- ------- -----
Profit Before Tax 64.6 19.6% 58.8 18.3% 160.3 14.5% 189.6 17.5%
Income Taxes 16.3 4.9% 13.6 4.2% 42.5 3.9% 43.9 4.0%
----- ----- ----- ----- ------- ----- ------- -----
Net Profit 48.3 14.6% 45.2 14.1% 117.8 10.7% 145.7 13.4%
Earnings per
share
Basic earnings
per common
share 0.18 0.17 0.43 0.55
Diluted earnings
per common
share 0.18 0.17 0.43 0.55
Average common
shares
outstanding 272.9 265.5 271.1 265.0
Average shares
assuming
dilution 272.9 265.5 271.2 265.0
Reported Segment Information
(Amounts in EUR millions)
For the three months ended December 31, 2024
Adjustments,
eliminations
Biopharmaceutical and
and Diagnostic unallocated
Solutions Engineering items Consolidated
------------------ ----------- ------------ ------------
External
Customers 279.4 51.2 -- 330.6
Inter-Segment 1.1 56.1 (57.2) --
----------------- ----------- ------------ ------------
Revenue 280.5 107.3 (57.2) 330.6
----------------- ----------- ------------ ------------
Gross Profit 87.2 20.0 (9.0) 98.2
----------------- ----------- ------------ ------------
Gross Profit
Margin 31.1% 18.6% 29.7%
----------------- ----------- ------------ ------------
Operating Profit 65.5 16.4 (15.0) 66.9
----------------- ----------- ------------ ------------
Operating Profit
Margin 23.3% 15.3% 20.2%
----------------- ----------- ------------ ------------
For the three months ended December 31, 2023
Adjustments,
eliminations
Biopharmaceutical and
and Diagnostic unallocated
Solutions Engineering items Consolidated
------------------ ----------- ------------ ------------
External
Customers 260.0 60.6 -- 320.6
Inter-Segment 0.6 40.6 (41.2) --
----------------- ----------- ------------ ------------
Revenue 260.6 101.2 (41.2) 320.6
----------------- ----------- ------------ ------------
Gross Profit 87.5 21.4 (7.1) 101.8
----------------- ----------- ------------ ------------
Gross Profit
Margin 33.6% 21.1% 31.8%
----------------- ----------- ------------ ------------
Operating Profit 61.7 15.5 (13.2) 64.0
----------------- ----------- ------------ ------------
Operating Profit
Margin 23.7% 15.3% 20.0%
----------------- ----------- ------------ ------------
For the year ended December 31, 2024
Adjustments,
eliminations
Biopharmaceutical and
and Diagnostic unallocated
Solutions Engineering items Consolidated
------------------ ----------- ------------ ------------
External
Customers 933.7 170.3 -- 1,104.0
Inter-Segment 4.0 187.3 (191.4) --
----------------- ----------- ------------ ------------
Revenue 937.8 357.6 (191.4) 1,104.0
----------------- ----------- ------------ ------------
Gross Profit 268.8 56.2 (22.6) 302.3
----------------- ----------- ------------ ------------
Gross Profit
Margin 28.7% 15.7% 27.4%
----------------- ----------- ------------ ------------
Operating Profit 165.6 33.1 (37.6) 161.1
----------------- ----------- ------------ ------------
Operating Profit
Margin 17.7% 9.3% 14.6%
----------------- ----------- ------------ ------------
For the year ended December 31, 2023
Adjustments,
eliminations
Biopharmaceutical and
and Diagnostic unallocated
Solutions Engineering items Consolidated
------------------ ----------- ------------ ------------
External
Customers 879.3 206.1 -- 1,085.4
Inter-Segment 2.0 166.7 (168.7) --
----------------- ----------- ------------ ------------
Revenue 881.3 372.8 (168.7) 1,085.4
----------------- ----------- ------------ ------------
Gross Profit 290.2 78.3 (28.6) 339.9
----------------- ----------- ------------ ------------
Gross Profit
Margin 32.9% 21.0% 31.3%
----------------- ----------- ------------ ------------
Operating Profit 187.6 53.6 (40.5) 200.7
----------------- ----------- ------------ ------------
Operating Profit
Margin 21.3% 14.4% 18.5%
----------------- ----------- ------------ ------------
Cash Flow
(Amounts in EUR millions)
For the three For the years
months ended ended December
December 31, 31,
2024 2023 2024 2023
------ -------- ------ --------
Cash flow from
operating
activities 43.6 10.2 155.8 105.2
Cash flow used
in investing
activities (91.0) (92.3) (310.2) (421.2)
Cash flow from
financing
activities 66.3 87.7 183.2 158.0
----- -------- ------ --------
Net change in
cash and cash
equivalents 18.9 5.6 28.8 (158.0)
----- -------- ------ --------
Non GAAP Financial Information
This press release contains non-GAAP financial measures. Please refer to "Non-GAAP Financial Information" on page 4 and the tables included in this press release for a reconciliation of non-GAAP financial measures.
Reconciliation of Revenue to Constant Currency Revenue
(Amounts in EUR millions)
Biopharmaceutical
Three months ended and Diagnostic
December 31, 2024 Solutions Engineering Consolidated
Reported Revenue
(IFRS GAAP) 279.4 51.2 330.6
Effect of changes
in currency
translation
rates 1.1 -- 1.1
----------------- ----------- ------------
Organic Revenue
(Non-IFRS GAAP) 280.5 51.2 331.7
----------------- ----------- ------------
Biopharmaceutical
Year ended and Diagnostic
December 31, 2024 Solutions Engineering Consolidated
Reported Revenue
(IFRS GAAP) 933.7 170.3 1,104.0
Effect of changes
in currency
translation
rates 3.8 0.1 3.9
----------------- ----------- ------------
Organic Revenue
(Non-IFRS GAAP) 937.5 170.4 1,107.9
----------------- ----------- ------------
Reconciliation of EBITDA
(Amounts in EUR millions)
For the three For the years
months ended ended December
December 31, Change 31, Change
2024 2023 % 2024 2023 %
--------------- ----- -------- ------ ----- -------- ------
Net Profit 48.3 45.2 6.8% 117.8 145.7 (19.2)%
Income Taxes 16.3 13.6 20.5% 42.5 43.9 (3.1)%
Finance Income (8.7) (4.3) 101.6% (22.3) (20.3) 10.3%
Finance
Expenses 10.9 9.5 13.9% 23.2 31.4 (26.2)%
---- -------- ------ ----- -------- ------
Operating
Profit 66.8 64.0 4.4% 161.1 200.7 (19.7)%
Depreciation
and
amortization
and impairment
of PPE 19.8 20.1 (1.6)% 80.7 78.5 2.8%
---- -------- ------ ----- -------- ------
EBITDA 86.6 84.1 3.0% 241.8 279.2 (13.4)%
---- -------- ------ ----- -------- ------
Calculation of Net Profit margin, Operating Profit Margin, Adjusted EBITDA
Margin and Adjusted Operating Profit Margin
(Amounts in EUR millions)
For the three months For the year
ended December 31, ended December 31,
2024 2023 2024 2023
------ -------- ------- --------
Revenue 330.6 320.6 1,104.0 1,085.4
Net Profit Margin (Net
Profit/ Revenue) 14.6% 14.1% 10.7% 13.4%
Operating Profit Margin
(Operating Profit/
Revenue) 20.2% 20.0% 14.6% 18.5%
Adjusted EBITDA Margin
(Adjusted EBITDA/
Revenue) 27.5% 27.0% 23.5% 26.9%
Adjusted Operating
Profit Margin (Adjusted
Operating Profit/
Revenue) 21.5% 20.8% 16.2% 19.6%
Reconciliation of Reported and Adjusted EBITDA, Operating Profit, Income
Taxes,
Net Profit, and Diluted EPS
(Amounts in EUR millions, except per share data)
Three months Income
ended December Operating Taxes Net Diluted
31, 2024 EBITDA Profit (4) Profit EPS
---------------- ------- --------- ------ ------ -------
Reported 86.6 66.8 16.3 48.3 0.18
Adjusting
items:
Start-up costs
new plants (1) 3.8 3.8 1.0 2.8 0.01
Restructuring
and related
charges (2) 0.4 0.4 0.1 0.3 0.00
Other severance
costs (3) 0.2 0.2 0.0 0.1 0.00
------ --------- ------ ------ -------
Adjusted 90.9 71.2 17.5 51.5 0.19
------ --------- ------ ------ -------
Adjusted Margin 27.5% 21.5% -- -- --
Three months
ended Income
December 31, Operating Taxes Net Diluted
2023 EBITDA Profit (4) Profit EPS
------------ ------- --------- ------ ------ -------
Reported 84.1 64.0 13.6 45.2 0.17
Adjusting
items:
Start-up
costs new
plants (1) 2.6 2.6 0.7 1.9 0.01
------ --------- ------ ------ -------
Adjusted 86.7 66.6 14.3 47.1 0.18
------ --------- ------ ------ -------
Adjusted
Margin 27.0% 20.8% -- -- --
Year ended Income
December 31, Operating Taxes Net Diluted
2024 EBITDA Profit (4) Profit EPS
---------------- ------- --------- ------ ------ -------
Reported 241.8 161.1 42.5 117.8 0.43
Adjusting
items:
Start-up costs
new plants (1) 13.0 13.0 3.5 9.5 0.04
Restructuring
and related
charges (2) 4.0 4.0 1.0 3.0 0.01
Other severance
costs (3) 0.4 0.4 0.1 0.3 0.00
------ --------- ------ ------ -------
Adjusted 259.2 178.5 47.1 130.6 0.48
------ --------- ------ ------ -------
Adjusted Margin 23.5% 16.2% -- -- --
Year ended Income
December 31, Operating Taxes Net Diluted
2023 EBITDA Profit (4) Profit EPS
---------------- ------- --------- ------ ------ -------
Reported 279.2 200.7 43.9 145.7 0.55
Adjusting
items: -- -- -- -- --
Start-up costs
new plants (1) 12.0 12.0 3.2 8.8 0.03
Restructuring
and related
charges (2) 0.3 0.3 0.1 0.2 0.00
------ --------- ------ ------ -------
Adjusted 291.5 213.0 47.2 154.7 0.58
------ --------- ------ ------ -------
Adjusted Margin 26.9% 19.6% -- -- --
(1) During the three months and the year ended December 31, 2024, the Group recorded EUR3.8 million and EUR13.0 million, respectively, of start-up costs for the new plants in Fishers, Indiana, United States, and in Latina, Italy. During the three months and the year ended December 31, 2023, the Group recorded EUR2.6 million and EUR12.0 million, respectively, of start-up costs for the new plants in Fishers, Indiana, United States, and in Latina, Italy. These costs are primarily related to labor costs incurred prior to the commencement of commercial operations that are associated with recruiting, hiring, training and travel expenses of personnel.
(2) During the three months and the year ended December 31, 2024, the Group recorded EUR0.4 million and EUR4.0 million, respectively, of restructuring and related charges among cost of sales, research and development, and general and administrative expenses. During the year ended December 31, 2023, the Group recorded EUR0.3 million of restructuring and related charges among general and administrative expenses. These charges are mainly employee costs related to the reorganization of certain business functions.
(3) During the three months and the year ended December 31, 2024, the Group recorded EUR0.2 million and EUR0.4 million, respectively, related to personnel expenses, including other severance costs.
(4) The income tax adjustment is calculated by multiplying the applicable nominal tax rate to the adjusting items.
Capital Employed
(Amounts in EUR millions)
As of December 31, As of December 31,
2024 2023
---------------------- ------------------- ------------------
- Goodwill and Other
intangible assets 83.6 81.0
- Right of Use assets 15.7 18.2
- Property, plant and
equipment 1,248.4 1,028.5
- Financial assets -
investments FVTPL 0.2 0.7
- Other non-current
financial assets 5.4 4.5
- Deferred tax assets 95.3 76.3
------------------------ ------------------ ------------------
Non-current assets
excluding FV of
derivative financial
instruments 1,448.7 1,209.2
------------------------ ------------------ ------------------
- Inventories 245.2 255.3
- Contract Assets 168.5 172.6
- Trade receivables 296.0 301.8
- Trade payables (231.0) (277.8)
- Advances from
customers (16.6) (22.9)
- Non-current advances
from customers (44.0) (39.4)
- Contract Liabilities (16.5) (22.3)
------------------------ ------------------ ------------------
Trade working capital 401.6 367.2
------------------------ ------------------ ------------------
- Tax receivables and
Other receivables 70.6 58.2
- Non-current assets
held for sale 0.2 --
- Tax payables and
Other liabilities (92.2) (107.0)
- Current Provisions (4.1) (1.1)
------------------------ ------------------ ------------------
Net working capital 376.1 317.4
------------------------ ------------------ ------------------
- Deferred tax
liabilities (12.6) (9.6)
- Employees benefits (7.2) (7.4)
- Non-Current
Provisions (2.8) (4.0)
- Other non-current
liabilities (62.7) (48.5)
------------------------ ------------------ ------------------
Total non-current
liabilities and
provisions (85.3) (69.5)
------------------------ ------------------ ------------------
Capital employed 1,739.4 1,457.1
------------------------ ------------------ ------------------
Net (debt)/ net cash (335.0) (324.4)
------------------------ ------------------ ------------------
Equity (1,404.4) (1,132.6)
------------------------ ------------------ ------------------
Total equity and net
debt (1,739.4) (1,457.1)
------------------------ ------------------ ------------------
Free Cash Flow
(Amounts in EUR millions)
For the three For the years
months ended ended December
December 31, 31,
2024 2023 2024 2023
------ -------- ------ --------
Cash Flow
from
Operating
Activities 43.6 10.2 155.8 105.2
Interest paid 3.6 0.7 7.4 3.1
Interest
received (0.4) (0.3) (1.3) (0.9)
Purchase of
property,
plant and
equipment (88.9) (82.0) (302.6) (433.2)
Proceeds from
sale of
property,
plant and
equipment -- 0.5 3.2 0.6
Purchase of
intangible
assets (2.3) (5.1) (11.0) (8.7)
----- -------- ------ --------
Free Cash
Flow (44.3) (76.0) (148.5) (333.9)
----- -------- ------ --------
Net (Debt) / Net Cash
(Amounts in EUR millions)
As of December 31, As of December 31,
2024 2023
------------------- ------------------
Non-current financial
liabilities (317.7) (255.6)
Current financial
liabilities (116.9) (143.3)
Other non-current
financial assets -
Fair value of
derivatives financial
instruments -- 0.6
Other current
financial assets 1.3 4.4
Cash and cash
equivalents 98.3 69.6
------------------ ------------------
Net (Debt)/ Net Cash (335.0) (324.4)
------------------ ------------------
CAPEX
(Amounts in EUR millions)
For the three For the year
months ended ended December
December 31, Change 31, Change
2024 2023 EUR 2024 2023 EUR
----- -------- ------ ----- -------- ------
Addition to
Property,
plants and
equipment
(1) 77.7 89.6 (11.9) 275.6 444.6 (169.0)
Addition to
Intangible
Assets 2.3 5.1 (2.9) 11.0 8.7 2.3
---- -------- ------ ----- -------- ------
CAPEX 80.0 94.7 (14.7) 286.6 453.3 (166.7)
---- -------- ------ ----- -------- ------
(1) For the year ended December 31, 2023 the addition related to the grant of land by the city of Fishers amounting to EUR8.3 million is excluded
Reconciliation of 2025 Guidance*
Reported and Adjusted EBITDA, Operating Profit, Net Profit, Diluted EPS
(Amounts in EUR millions, except per share data)
Operating
Revenue EBITDA Profit Net Profit Diluted EPS
------------ ---------------- ----------- ----------- ----------- -----------
Reported 1,160-0-1,190.0 284.8-298.1 180.9-194.2 132.0-142.2 0.48-0.52
Adjusting
items:
Start-up costs new plants 8.2 8.2 6.3 0.03
----------- ----------- ----------- -----------
Adjusted 1,160.0-1,190.0 293.0-306.3 189.1-202.3 138.3-148.5 0.51-0.55
----------------- ----------- ----------- ----------- -----------
*Amounts may not add due to rounding
View source version on businesswire.com: https://www.businesswire.com/news/home/20250306463087/en/
CONTACT: Media
Stevanato Group
media@stevanatogroup.com
Investor Relations
Lisa Miles
lisa.miles@stevanatogroup.com
(END) Dow Jones Newswires
March 06, 2025 06:31 ET (11:31 GMT)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。